Cardio3 tests Europe's appetite for biotech IPOs

The big surge of biotech IPOs over the last few months has largely been restricted to the United States. But now a European biotech with a Phase III heart therapy in the clinic will see if it can get the mojo working on the continent. Belgium's Cardio3 BioSciences said today that it is plotting an IPO, but didn't spell out how much the company was planning to raise. Reuters reports that Belgium hasn't seen an IPO since Movetis went public four years ago. A couple of weeks ago Cardio3 said it raised $24 million from investors. Story